Ling Han1, Joseph V Agostini, Heather G Allore. 1. Department of Internal Medicine, Program on Aging, Yale University School of Medicine, New Haven, Connecticut 06511, USA. ling.han@yale.edu
Abstract
OBJECTIVES: To examine the longitudinal relationship between cumulative exposure to anticholinergic medications and memory and executive function in older men. DESIGN: Prospective cohort study. SETTING: A Department of Veterans Affairs primary care clinic. PARTICIPANTS: Five hundred forty-four community-dwelling men aged 65 and older with diagnosed hypertension. MEASUREMENTS: The outcomes were measured using the Hopkins Verbal Recall Test (HVRT) for short-term memory and the instrumental activity of daily living (IADL) scale for executive function at baseline and during follow-up. Anticholinergic medication use was ascertained using participants' primary care visit records and quantified as total anticholinergic burden using a clinician-rated anticholinergic score. RESULTS: Cumulative exposure to anticholinergic medications over the preceding 12 months was associated with poorer performance on the HVRT and IADLs. On average, a 1-unit increase in the total anticholinergic burden per 3 months was associated with a 0.32-point (95% confidence interval (CI)= 0.05-0.58) and 0.10-point (95% CI=0.04-0.17) decrease in the HVRT and IADLs, respectively, independent of other potential risk factors for cognitive impairment, including age, education, cognitive and physical function, comorbidities, and severity of hypertension. The association was attenuated but remained statistically significant with memory (0.29, 95% CI=0.01-0.56) and executive function (0.08, 95% CI=0.02-0.15) after further adjustment for concomitant non-anticholinergic medications. CONCLUSION: Cumulative anticholinergic exposure across multiple medications over 1 year may negatively affect verbal memory and executive function in older men. Prescription of drugs with anticholinergic effects in older persons deserves continued attention to avoid deleterious adverse effects.
OBJECTIVES: To examine the longitudinal relationship between cumulative exposure to anticholinergic medications and memory and executive function in older men. DESIGN: Prospective cohort study. SETTING: A Department of Veterans Affairs primary care clinic. PARTICIPANTS: Five hundred forty-four community-dwelling men aged 65 and older with diagnosed hypertension. MEASUREMENTS: The outcomes were measured using the Hopkins Verbal Recall Test (HVRT) for short-term memory and the instrumental activity of daily living (IADL) scale for executive function at baseline and during follow-up. Anticholinergic medication use was ascertained using participants' primary care visit records and quantified as total anticholinergic burden using a clinician-rated anticholinergic score. RESULTS: Cumulative exposure to anticholinergic medications over the preceding 12 months was associated with poorer performance on the HVRT and IADLs. On average, a 1-unit increase in the total anticholinergic burden per 3 months was associated with a 0.32-point (95% confidence interval (CI)= 0.05-0.58) and 0.10-point (95% CI=0.04-0.17) decrease in the HVRT and IADLs, respectively, independent of other potential risk factors for cognitive impairment, including age, education, cognitive and physical function, comorbidities, and severity of hypertension. The association was attenuated but remained statistically significant with memory (0.29, 95% CI=0.01-0.56) and executive function (0.08, 95% CI=0.02-0.15) after further adjustment for concomitant non-anticholinergic medications. CONCLUSION: Cumulative anticholinergic exposure across multiple medications over 1 year may negatively affect verbal memory and executive function in older men. Prescription of drugs with anticholinergic effects in older persons deserves continued attention to avoid deleterious adverse effects.
Authors: Joseph T Hanlon; Gerda G Fillenbaum; Maggie Kuchibhatla; Margaret B Artz; Chad Boult; Cynthia R Gross; Judith Garrard; Kenneth E Schmader Journal: Med Care Date: 2002-02 Impact factor: 2.983
Authors: Sarah N Hilmer; Donald E Mager; Eleanor M Simonsick; Ying Cao; Shari M Ling; B Gwen Windham; Tamara B Harris; Joseph T Hanlon; Susan M Rubin; Ronald I Shorr; Douglas C Bauer; Darrell R Abernethy Journal: Arch Intern Med Date: 2007-04-23
Authors: Gail Kuslansky; Mindy Katz; Joe Verghese; Charles B Hall; Pablo Lapuerta; Gia LaRuffa; Richard B Lipton Journal: Arch Clin Neuropsychol Date: 2004-01 Impact factor: 2.813
Authors: Juho Uusvaara; Kaisu H Pitkala; Hannu Kautiainen; Reijo S Tilvis; Timo E Strandberg Journal: Drugs Aging Date: 2011-02-01 Impact factor: 3.923
Authors: N L Campbell; M A Boustani; K A Lane; S Gao; H Hendrie; B A Khan; J R Murrell; F W Unverzagt; A Hake; V Smith-Gamble; K Hall Journal: Neurology Date: 2010-07-13 Impact factor: 9.910
Authors: Elizabeth J Geller; Andrea K Crane; Ellen C Wells; Barbara L Robinson; Mary L Jannelli; Christine M Khandelwal; Annamarie Connolly; Brent A Parnell; Catherine A Matthews; Julie B Dumond; Jan Busby-Whitehead Journal: Clin Drug Investig Date: 2012-10-01 Impact factor: 2.859
Authors: Birgit Böhmdorfer; Sonja Rohleder; Martin Wawruch; T J M van der Cammen; Thomas Frühwald; Christian Jagsch; Susanne Melitta Maria Janowitz; Marietta Nagano; Mirko Petrovic; Ulrike Sommeregger; Bernhard Iglseder Journal: Z Gerontol Geriatr Date: 2015-08-19 Impact factor: 1.281